Clinical Trial Update: Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of dimethylfumarate (DMF) in patients with cutaneous T cell lymphoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Dimethylfumarate (dimethylfumarate)

Snippet

Sponsor: Universitätsmedizin Mannheim | Conditions: Cutaneous T Cell Lymphoma | Phase 2 | Status: COMPLETED